Price Chart

Executive Summary

Forte Biosciences had four shelf registration statements (File Nos. 333-296425, 333-283814, 333-274257, 333-224880) declared effective by the SEC on September 1, 2026. These EFFECT notices clear the way for the company to conduct offerings under each shelf, including the $500M universal shelf filed in June 2026. For a clinical-stage biopharma burning ~$22M/quarter with $58.2M cash, this makes near-term capital raising highly probable, creating a significant dilution overhang that outweighs any positive pipeline developments.

Key Facts

• Four shelf registration statements (File Nos. 333-296425, 333-283814, 333-274257, 333-224880) declared effective on September 1, 2026.
• The $500M universal shelf (File No. 333-296425) was previously filed on June 6, 2026 and is now effective.
• Forte is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026.
• The shelf represents massive potential dilution relative to the company's market cap, enabling the company to sell common stock, preferred stock, debt, and warrants.

Financial Impact

Up to $500M in securities can now be offered, representing substantial dilution relative to the company's market cap

Risk Factors

• Imminent dilutive offering likely given cash burn trajectory
• Potential for multiple offerings from separate shelf registrations
• No revenue to offset dilution — all funding must come from equity or debt markets

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 12 SEC documents filed with EDGAR.

US Market Status